Eligible Applicants and Regions

The call is open to legal entities from EU Member States and Horizon Europe Associated Countries, including companies, SMEs, research institutes, universities, technology centres, hospitals, public administrations, associations, and NGOs. All participants must have a validated Participant Identification Code (PIC).

Only beneficiaries established in regions covered by a participating Funding Agency are eligible to receive PRECISEU financial support. These funding regions include Catalonia (Spain), Baden-Württemberg (Germany), Nord-Est (Romania), Emilia-Romagna (Italy), Lithuania, Crete (Greece), Castilla-La Mancha (Spain), Lazio (Italy), and Ireland. Entities from other PRECISEU regions (e.g., Bulgaria, Flanders, Gothenburg, Netherlands, Madrid, Rivne) or other EU/Associated Countries may participate on a self-funded basis, provided their participation is strategically necessary and their financial resources are secured.

Consortium Requirements

Each consortium must meet the following conditions:

• Include at least three independent legal entities established in three different Funding Agency regions.
• At least two of these three entities must be established in two different EU Member States.
• Each of these three core entities must be eligible for, and request, funding from their respective participating Funding Agency.
• Include at least one SME from a PRECISEU region.
• A consortium may include at most one partner from a PRECISEU non-funding region and at most one partner from a non-PRECISEU region (EU Member State or Horizon Europe Associated Country). These non-funded partners must provide proven added value, their budget must represent less than 20% of the consortium budget, and their financial resources must be secured.
• Only entities from PRECISEU funding regions may coordinate a proposal.

Applicants must not be in an exclusion situation, as defined by EU Financial Regulation (e.g., bankruptcy, fraud, grave professional misconduct).

Project Duration

Projects must fit within the overall implementation window from October 2026 to March 2029. The exact project duration should be justified by the proposed work, and applicants should verify if regional annexes impose stricter end dates.

Participation in Multiple Proposals

Entities can participate in more than one proposal, provided they only submit one as Coordinator, the proposals differ from each other, and the teams involved are different within the applicant entity.

Application and Submission

The application process follows a single-stage procedure. Proposals must be prepared in English, using the official templates (Part A - Administrative Data, Part B - Description of Action, Part C - Budget, and Declaration of Honour), and uploaded through the PRECISEU website. Part B is limited to 30 pages; any pages beyond this limit will not be considered. The coordinator is responsible for submitting the application electronically, though some regions may require an additional regional or national submission.

Evaluation and Selection

An eligibility check is performed before the scientific evaluation. Eligible proposals undergo an independent evaluation by an Expert Panel, consisting of a two-step process:

• Step 1: Individual Evaluation - Each proposal is evaluated independently by a minimum of three experts.
• Step 2: Consensus Evaluation - The Expert Panel ranks proposals based on evaluation criteria.

Scores range from 0 to 5 per criterion, with a minimum threshold of 3 for each criterion and an overall threshold of 10. In case of a tie, the Impact score is considered first, followed by Relevance. Funding decisions are made by relevant Funding Agencies based on the ranking and available regional budgets, with additional criteria for oversubscription.

Coordinators receive an Evaluation Result Letter. A formal Evaluation Review Procedure is available for procedural errors, with requests to be submitted within 7 calendar days from the date of the letter.

Post-Award Workflow

Successful projects proceed to a Grant Agreement preparation phase, where a sub-Grant Agreement is signed between the PRECISEU Coordinator and the JIP Coordinator. A Consortium Agreement is also required between all JIP participants. Regional annexes will detail specific funding conditions and obligations for beneficiaries.

Monitoring and Reporting

Projects are required to submit one mid-term interim report at month 18 and a final technical report within 30 days after the project end. Monitoring focuses primarily on technical implementation and achievement of results. Beneficiaries must keep records for five years after the balance payment.

Audits and Controls

The European Innovation Council and SMEs Executive Agency (EISMEA), European Commission, OLAF, EPPO, and ECA have powers of control. While the call uses a lump-sum model, some Funding Agencies may impose additional regional requirements for financial control, audit, expenditure verification, or cost reporting. There is no automatic obligation for a Certificate on the Financial Statements (CFS).

Timeline of the Call

Eligible proposals are evaluated against three award criteria, with scores ranging from 0 to 5 for each. A minimum threshold of 3 per criterion and an overall minimum threshold of 10 apply.

Evaluation Criteria

Scoring Mechanism and Tie-breaking

In the event that two or more proposals obtain the same final score, proposals will be ranked first by their score under the Impact criterion, followed by Relevance. If a tie still remains, additional considerations aligned with the objectives of the call may be applied by the evaluation panel to determine the final ranking, such as maximising the number of high-quality projects funded, ensuring optimal use of available regional budgets, and encouraging participation from underrepresented or undersubscribed regions.

Evaluation Process

The evaluation consists of a two-step process:

1. Individual Evaluation: Each proposal is evaluated independently by a minimum of three experts.
2. Consensus Evaluation: An Expert Panel ranks the proposals, submitting a list of recommendations for funding to the Call Secretariat.

All experts are subject to Conflict of Interest (COI) checks and confidentiality obligations.

Funding Model and Budget

The PRECISEU Open Call uses a lump-sum funding model. The overall open call budget is €11,570,000. The maximum financial contribution per project is €3,000,000, and the maximum amount a single legal entity may receive across all participating projects is €600,000 (subject to negotiation if exceeded).

Funding Rates

Unless a regional annex specifies otherwise, the general funding rates are:

• Non-profit legal entities located in PRECISEU funding regions: Up to 100%.
• Profit-making legal entities located in PRECISEU funding regions: Up to 70%.
• Any entity in PRECISEU non-funding regions or outside the PRECISEU geography: 0% (self-funded).

For non-profit entities engaged in non-economic activities, 100% funding may apply, provided a separate accounting system is maintained.

Eligible Costs

Unless specified otherwise in a regional annex, eligible costs include:

• Direct staff costs.
• Subcontracting costs for additional or complementary tasks (not core project tasks, not between partners), limited to 20% of the total eligible costs of the project.
• Other direct costs such as travel, consumables, and equipment depreciation.
• Indirect costs, calculated automatically as 25% of eligible direct costs (excluding subcontracting).

Double funding and costs incurred outside the project duration are strictly prohibited.

Payment Schedule

As a general rule, and unless regional annexes state otherwise, funded projects receive a pre-financing of 50% of the granted contribution, normally within 30 days from the Grant Agreement signature. The balance payment is made within 60 days from the completion of the assessment of the final progress performance report. However, payment modalities, including pre-financing rates, interim payments, reimbursement schedules, and guarantee requirements, may vary significantly by region, as detailed in the regional annexes.

State Aid Considerations

Financial support must comply with applicable State aid rules. This may involve the de minimis regime (max €300,000 over 3 years per single undertaking) or Article 25 GBER for research and development projects. Under Article 25 GBER, maximum aid intensities for experimental development are:

• Large enterprise: 50%
• Medium-sized enterprise: 60%
• Small enterprise: 70%

Funding Agencies and Indicative Envelopes

Funding is provided by participating Funding Agencies, each with an indicative envelope:

Due to differences in regional budgets, not all highly ranked proposals may be funded in situations of oversubscription. Consortia may be invited to revise their budget or composition.

The PRECISEU Open Call places a strong emphasis on interregional collaboration and the strengthening of innovation ecosystems across Europe. Projects are expected to demonstrate a genuine European and interregional logic, featuring complementary partners and a clear justification for the necessity of the interregional setting.

Key expectations for collaborations include:

• Strengthening collaboration between research, industry, healthcare providers, and regional authorities to facilitate the uptake of personalised medicine innovations by the market.
• Promoting cross-regional innovation alliances and knowledge transfer between ecosystems.
• Enhancing connections between different PRECISEU innovation ecosystems across Europe to advance towards truly personalised healthcare.
• Contributing to the transfer of practices and solutions among European regions.
• Participating in networking and joint activities, such as workshops, knowledge exchange, development of best practices, and joint communication activities. Proposals should budget for attendance at regular joint meetings.

The call explicitly seeks proposals that connect technical progress with regional and European added value, explaining how the interregional work will contribute to more effective, equitable, and scalable personalised medicine solutions.

The project implementation framework requires a comprehensive and integrated approach across the application parts. Part B - Description of the Action is the core, demanding a consistent narrative that links objectives, results, impact pathways, and the work plan.

Proposal Structure and Content

• Relevance: Applicants must articulate the project's vision, ambition, and objectives (general, specific, operational), demonstrating how the work goes beyond the state of the art and positions the project along relevant Technology Readiness Levels (TRL 6-8). The methodology should be robust, realistic, and integrate open science practices where appropriate.
• Quality: This section must demonstrate a manageable and well-resourced work plan, including a clear work package structure, realistic task sequencing, coherent timetable, and justified resource allocation. Due visibility should be given to project management, data management, dissemination, exploitation, and communication activities. Deliverables and milestones should serve as control instruments, and risks must be honestly presented with credible mitigation measures.
• Impact: Proposals must explain how project results will create a difference beyond the immediate implementation, contributing to the call's expected outcomes and impacts. This includes identifying target groups, quantifying expected changes, and detailing measures for dissemination, exploitation, and communication, along with a proportionate intellectual property strategy.

Cross-Cutting Requirements

Projects must address several cross-cutting requirements:

• Integration of Gender Dimension: Applicants are strongly encouraged to integrate sex and gender considerations in research content and implementation, aiming for better gender balance in personnel.
• Ethical Dimension: Ethical compliance is pivotal, requiring applicants to describe potential ethical aspects and how the project will fulfil applicable institutional, regional, national, and EU legislation. Only ethically cleared proposals will be funded.
• Security: Activities must comply with applicable security rules, including protection of classified information.
• Involvement of Potential End-Users: Active involvement of end-users (patients, healthcare providers, citizens) is strongly encouraged to guide work towards specific applications and improve success.
• Open Science and Open Access: Projects are expected to develop Data Management Plans (DMPs) early on, ensuring data is Findable, Accessible, Interoperable, and Re-usable (FAIR). Open access to generated research data is required "as open as possible as closed as necessary."
• Intellectual Property Management: Applicants must describe their IP strategy, including protection measures, consistent with State aid frameworks. A consortium agreement covering background, access rights, ownership of results, protection, exploitation, dissemination, confidentiality, and dispute resolution is mandatory before grant signature.
• Do No Significant Harm (DNSH) Principle: Projects must comply with DNSH across six environmental objectives.
• Responsible Research and Innovation (RRI): Proposals should adhere to RRI principles, identifying and addressing social, ethical, legal, political, environmental, and cultural dimensions, and involving relevant stakeholders.

Joint Activities and Monitoring

All funded projects are encouraged to participate in networking and joint activities, such as workshops, knowledge exchange, development of best practices, and joint communication. Proposals should include a budget for attendance at regular joint meetings. The details of these joint activities will be defined during the first month of the project and compiled in a Dissemination plan.

Monitoring includes a mid-term interim report at month 18 and a final technical report within 30 days after project end, evaluating work plan fulfilment, continued relevance, and potential impact.

Applicants must describe their IP management strategy in the proposal, including protection and exploitation where relevant. This strategy should be outlined in the 'Measures to maximise impact - Dissemination, exploitation and communication' section of Part B, detailing foreseen protection measures such as patents, design rights, copyright, trade secrets, and how these would be used to support exploitation.

Selected consortia must put in place a consortium agreement before grant signature. This agreement must cover background, access rights, ownership of results, protection, exploitation, dissemination, confidentiality, and dispute resolution. Results belong to the beneficiaries that generate them, unless otherwise agreed in the consortium agreement. Funding Agencies do not take ownership of results, although they retain certain rights of use over non-sensitive materials submitted for reporting, communication, or dissemination purposes.

The call contains a dedicated ethical dimension section, and applicants must address ethics where relevant. Ethically sensitive activities may require screening, approvals, permits, or other compliance measures, and only ethically cleared proposals should proceed to funding. Applicants should also ensure compliance with data protection, security, and wider legal requirements.

The Ethics Self-Assessment section in Part B, which does not count towards the 30-page limit, requires applicants to tick appropriate boxes if their project involves:

• Processing of personal data
• Human participants (with or without consent)
• A risk to the environment or society
• The use of AI-based applications
• The use of animals in any capacity
• The use of human or other biological tissues
• Instructions designed to facilitate harmful, illegal, or otherwise unethical uses
• Any other ethical issues that should be taken into consideration.

If any of these boxes are ticked, applicants must detail and indicate how they plan to address the ethical issue.

The proposal evaluation criteria include the quality of open science practices, specifically mentioning the sharing and management of research outputs. Applicants are advised to give due visibility in the work plan to 'data management', either with distinct tasks or distinct work packages.

Multi-Actor Approach

The call requires a multi-actor approach, expecting consortia to strengthen collaboration between diverse stakeholders. This includes research, industry, healthcare providers, and regional authorities, aiming for the uptake of personalised medicine innovations by the market. Target organisations encompass SMEs, start-ups, public and private research bodies, hospitals, NGOs (including patient organisations), and large companies. The active involvement of end-users (patient organisations, citizens, healthcare providers, and health and social care service users) is strongly encouraged to guide the work and improve solution success.

Interdisciplinarity

The call explicitly references the importance of interdisciplinary research efforts as crucial for the effective development of personalised medicine, aligning with the IC PerMed Strategic Research and Innovation Agenda.

Social Sciences and Humanities (SSH)

The integration of the gender dimension is a requirement, with applicants strongly encouraged to integrate sex and gender considerations, as well as those for underrepresented populations or patient sub-groups, in the research and innovation content. Proposals should also address social and health determinants, including sex, gender, age, socio-economic status, living in rural/remote areas, and education. Furthermore, adherence to Responsible Research and Innovation (RRI) principles requires identifying and addressing relevant social, ethical, legal, political, environmental, and/or cultural dimensions of the proposed innovation.

The complete application must include a Declaration of Honour. Funded projects must comply with the sub-grant agreement and any additional regional conditions. For self-funded partners, their financial resources must be secured at the application stage and before Grant Agreement signature.

After receiving funding, projects must comply with the sub-grant agreement, reporting and monitoring obligations, supporting-document requirements, and any additional regional conditions. Beneficiaries may also be subject to further expenditure verification, audit, or supporting-document obligations imposed by the relevant Funding Agency. Projects are also expected to participate in networking and joint activities where appropriate.

A review procedure is available only for procedural errors, not for disagreements with scores or comments. Only the Coordinator may request a review, normally within 7 calendar days from the Evaluation Result Letter.

Frequently Asked Questions

Version 1 13/04/2026

This FAQ document is a living document and will be subject to continuous revision and updates. The version number will be updated accordingly each time modifications are introduced. Applicants are encouraged to consult the latest available version regularly.

TABLE OF CONTENTS

1. What is PRECISEU and what are its objectives?

PRECISEU is a Horizon Europe co-funded project that aims to connect innovation ecosystems across Europe and accelerate the uptake of personalised medicine. It focuses in particular on deep-tech innovation in health, especially advanced therapies and health data, while promoting interregional collaboration, transfer of practices, and scaling up innovation capacity across participating ecosystems.

2. What is the objective of the PRECISEU Open Call?

The objective of the Open Call is to fund Joint Interregional Projects (JIPs) that support the scale-up and validation of deep-tech innovations in personalised medicine, strengthen collaboration between PRECISEU ecosystems, and contribute to the expected outcomes and impacts defined in the call. Projects are expected to help bring solutions from TRL 6 towards TRL 8.

3. What types of projects are supported?

The call supports Innovation Action-type collaborative projects. Eligible activities include, among others, scale-up production, optimisation and validation of methods and protocols, mechanism-related studies linked to technical uncertainty, development of reference materials and improved models, generation of evidence for performance, safety or regulatory readiness, end-user collaborative projects, use of health data repositories, and validation or demonstration activities in relevant or operational environments where needed to resolve remaining technical uncertainty.

4. Which sectors and thematic areas are prioritised?

The call prioritises deep-tech innovation in personalised medicine, with a particular focus on advanced therapies and health data. Projects must also fit the technical scope and priorities described in the call and its annexes.

5. Who can apply?

Applicants may include companies, research institutes, universities, technological centres, local authorities, public administrations, associations, NGOs including patient organisations, public and private research bodies, hospitals, and large companies, provided they are legal entities and have a validated PIC number. The PIC number have to be validated before the Grant Agreement Signature. However, funding eligibility depends on the applicant's region and the applicable regional annex.

6. What are the consortium requirements?

Each consortium must include at least three independent legal entities established in three different Funding Agency regions, and at least two of those entities must be in two different EU Member States. The consortium must include at least one SME from a PRECISEU funding region. Only entities established in territories of participating Funding Agencies may lead the consortium and receive PRECISEU funding. A consortium may include at most one partner from a PRECISEU non-funding region and/or one partner from a non-PRECISEU EU Member State or Horizon Europe Associated Country, subject to the call conditions; those participants are self-funded.

7. Can organisations from non-funding regions participate?

Yes, but on a self-funded basis. Their participation must provide clear added value, their budget must remain below the threshold set by the call, and their financial resources must be secured at application stage and before Grant Agreement signature. They cannot lead the consortium.

8. What results are expected from funded projects?

Projects are expected to contribute to the call's expected outcomes and impacts through results such as validated prototypes, harmonised protocols, interoperable data infrastructures, clinical or real-world evidence, regulatory- and HTA-relevant documentation, sustainable business and implementation models, capacity-building outcomes, best-practice guidelines, or strengthened use of health data for clinical decision-making and regulatory acceptance.

9. What is the available funding?

The total budget committed to this Open Call is EUR 11 570 000. The maximum financial contribution per project is EUR 3 000 000, and the maximum amount that may be awarded to a single beneficiary is EUR 600 000, subject to the applicable regional rules and available regional budgets.

10. What funding rates apply?

Funding rates may differ depending on the region, the type of beneficiary, and the applicable State aid framework. As a general rule under the PRECISEU Open Call, entities established in PRECISEU Funding Agency regions may receive up to 70% funding if they are profit-making entities and up to 100% funding if they are non-profit entities, unless the relevant regional annex provides otherwise. Where Article 25 GBER applies to experimental development, aid intensity may also depend on enterprise size and on the applicable increases under Article 25(6)(a) and, where relevant, Article 25(6)(d). For the purposes of this Open Call, the call indicates maximum aid intensities of 50% for large enterprises, 60% for medium-sized enterprises, and 70% for small enterprises, subject in all cases to the regional annex and the final confirmation of the competent Funding Agency.

11. Do partners need to co-finance the project?

Yes, where the applicable funding rate does not cover 100% of eligible costs. In particular, for-profit entities may need to cover the non-funded share of their project costs. In addition, self-funded partners must demonstrate that their own resources are secured. Regional State aid and funding-rate rules may also affect the financing structure.

12. What costs are eligible for funding?

Eligible costs are governed by the call and, where relevant, by Annex 1 and the applicable regional rules. Applicants must pay particular attention to regional specificities on beneficiary types, cost categories, State aid conditions, pre-financing, audit requirements, and documentation obligations. The call also states that additional regional expenditure-verification or audit requirements may apply.

13. How do I submit an application?

Applications must be submitted electronically through the online application form available on the PRECISEU website. The submission is single-stage and must use the official templates. The complete application must include Part A, Part B, Part C, and the Declaration of Honour. Part B is limited to 30 pages. All documents must be uploaded in PDF format, and the application must be uploaded by the Coordinator. Some regions may also require additional submissions directly to the relevant Funding Agency.

14. In which language must the proposal be submitted?

Applications must be written exclusively in English. Submissions in any other language are ineligible.

15. What are the key deadlines?

The Open Call is scheduled to open on 13 April 2026 and close on 14 June 2026 at 17:00 CET. Evaluation is foreseen from 15 June 2026 to 31 July 2026, results are expected on 31 July 2026, Grant Agreement preparation is planned from 1 August 2026 to 30 September 2026, the signature deadline is 30 September 2026, the earliest project start date is 1 October 2026, and the latest project end date is 31 March 2029.

16. What are the evaluation criteria?

Proposals are evaluated against three award criteria: Excellence, Impact, and Quality and efficiency of the implementation. The call follows an IA-like logic aligned with Horizon Europe evaluation practice.

17. How are proposals scored?

Each criterion is scored from 0 to 5, with a minimum threshold of 3 per criterion; half marks may be awarded. The overall threshold is 10 points across the three criteria. In case of a tie, proposals are ranked first by Impact, then by Excellence, and if needed by further call-aligned considerations.

18. How does the evaluation process work?

The evaluation has two steps: individual evaluation by at least three experts, followed by consensus evaluation by the Expert Panel. Only proposals that pass the admissibility and eligibility check proceed to independent evaluation. The Call Secretariat then communicates results and the funding recommendation goes to the PRECISEU Steering Committee.

19. Can I submit more than one application?

Yes. An organisation may participate in more than one proposal provided that it acts as Coordinator in only one, the proposals are genuinely different, and the teams involved within the organisation are different.

20. Can I modify my application after submission?

The call text confirms that, after submission, the Coordinator receives a verification email with the submission date and time, but it does not establish a general right to amend the proposal after the deadline. As a rule, applicants should assume that a proposal must be complete and correct at submission. Any admissible corrections would only be those allowed by the submission system or specifically requested during Grant Agreement preparation for successful proposals.

21. What happens if a consortium partner withdraws?

Any change affecting consortium composition after selection would need to be addressed during Grant Agreement preparation or, later, under the amendment rules of the sub-grant agreement and applicable regional conditions. Because eligibility depends on consortium structure, withdrawal of a core funded partner may jeopardise eligibility or require a justified replacement.

22. Are there ethics requirements?

Yes. The call contains a dedicated ethical dimension section, and applicants must address ethics where relevant. Ethically sensitive activities may require screening, approvals, permits, or other compliance measures, and only ethically cleared proposals should proceed to funding. Applicants should also ensure compliance with data protection, security, and wider legal requirements.

23. Do projects need to meet sustainability or DNSH requirements?

Yes. Projects must comply with the Do No Significant Harm (DNSH) principle and should address relevant sustainability considerations where applicable. The call also expects applicants to take account of broader Responsible Research and Innovation dimensions.

24. What are the obligations after receiving funding?

Funded projects must comply with the sub-grant agreement, reporting and monitoring obligations, supporting-document requirements, and any additional regional conditions. Beneficiaries may also be subject to further expenditure verification, audit, or supporting-document obligations imposed by the relevant Funding Agency. Projects are also expected to participate in networking and joint activities where appropriate.

25. What are the rules regarding intellectual property?

Applicants must describe their IP management strategy in the proposal, including protection and exploitation where relevant. Selected consortia must put in place a consortium agreement before grant signature covering background, access rights, ownership of results, protection, exploitation, dissemination, confidentiality, and dispute resolution. Results belong to the beneficiaries that generate them, unless otherwise agreed in the consortium agreement. Funding Agencies do not take ownership of results, although they retain certain rights of use over non-sensitive materials submitted for reporting, communication, or dissemination purposes.

26. Are there tools or resources to help applicants?

Yes. The PRECISEU consortium provides call documents and support materials, and the project framework foresees a Guide for Applicants. The Call Secretariat acts as the main contact point, and regional Funding Agencies may provide additional support on regional conditions. The call also refers applicants to resources such as the European IP Helpdesk where relevant.

27. Is there a review procedure if I disagree with the evaluation result?

Yes, but only for procedural errors. The Evaluation Review Procedure does not allow re-evaluation simply because the applicant disagrees with the scores or comments. Only the Coordinator may request review, and the request must normally be submitted within 7 calendar days from the Evaluation Result Letter.

28. Where can I find more information or ask questions?

For general enquiries, applicants may contact the Call Secretariat at preciseu@biocat.cat and consult the PRECISEU website. Questions related to regional funding conditions should be addressed to the relevant Funding Agency contacts listed in Annex 1.

Part B - Description of Action

The Part B - Description of Action is limited to a maximum of 30 pages. Applicants are advised to delete instructions in blue and grey text to stay within this limit. The content included from the Ethics section onwards will not be counted towards the 30-page limit.

The structure of Part B includes the following main sections:

• Relevance: Clarity and pertinence of objectives, ambition beyond state-of-the-art, soundness of methodology, interdisciplinary approaches, gender dimension, and quality of open science practices.
• Objectives and ambition of the project: Outline common vision, ambition, general, specific, and operational objectives, expected timeframe, how the project goes beyond the state-of-the-art, and Technology Readiness Level (TRL) at start and end.
• Methodology: Describe the overall methodology, concepts, models, assumptions, and how the gender dimension is taken into account.
• Quality: Quality and effectiveness of the work plan, risk assessment, appropriateness of effort and resources.
• Work plan and resources: Brief presentation of the overall structure, timing (Gantt chart), inter-relation (Pert chart), detailed work description, work package descriptions, list of deliverables, list of milestones, and critical risks with mitigation measures. A distinct work package for 'project management' and visibility for 'data management', 'dissemination and exploitation', and 'communication activities' are advised.
• Capacity of participants and consortium as a whole: Describe how the consortium matches objectives, brings necessary expertise, access to critical infrastructure, and the role of each participant. Justification is required for participants from non-funding regions.
• Work Package description: Detailed description for each work package, including objectives, description of work (broken into tasks, lead partner, role of participants, quantified work), and linked deliverables.
• List of deliverables: Table including Deliverable No, Name, Short description, WP number, Lead participant, Type, Dissemination level, and Delivery date.
• List of milestones: Table including Milestone No, Name, Related WP, Lead participant, Delivery date, and Means of verification.
• Critical risks for implementation: Table including Description of risk (likelihood, severity), WP involved, and Proposed risk-mitigation measures.
• Impact: Contribution to outcomes and impacts, scale and significance, and measures to maximise impacts.
• Project's pathways towards impact: Narrative explaining how results make a difference, unique contribution to call outcomes and wider impacts, target groups, potential negative environmental outcomes, scale and significance of contribution, and requirements/barriers with mitigating measures.
• Measures to maximise impact - Dissemination, exploitation and communication: Describe planned measures, target groups, IP management strategy, protection measures (patents, design rights, copyright, trade secrets), and how these support exploitation.
• Summary: Canvas to present key elements of project impact pathway and measures to maximise impact.

Applications must be submitted electronically through the online application form on the PRECISEU website. The complete application must include Part A, Part B, Part C, and the Declaration of Honour. All documents must be uploaded in PDF format, and the application must be uploaded by the Coordinator. Some regions may also require additional submissions directly to the relevant Funding Agency.

The complete application must include Part C. Eligible costs are governed by the call and, where relevant, by Annex 1 and the applicable regional rules. Applicants must pay particular attention to regional specificities on beneficiary types, cost categories, State aid conditions, pre-financing, audit requirements, and documentation obligations. The call also states that additional regional expenditure-verification or audit requirements may apply.